Our previous study reported that ACSL4-high expression in tumor tissue was correlated with good prognosis in HCC patients treated with sorafenib, due to ACSL4's role in promoting ferroptosis induced by sorafenib [6]. This evidence concerns the gene ACSL4 and hepatocellular carcinoma.